Optimal Pathological Response in LACC After Neoadjuvant Chemoimmunotherapy Shows Promising Short-Term Survival
Good news for advanced cervical cancer patients
A retrospective real-world analysis of 89 patients with locally advanced cervical cancer treated with neoadjuvant chemoimmunotherapy and rad…
Women with advanced cervical cancer who respond well to initial treatment show over 90% survival and may avoid harsh follow-up drugs.
Pembrolizumab ranks highest for survival in cervical cancer network meta-analysis
Review finds pembrolizumab may improve survival in advanced cervical cancer
A Bayesian network meta-analysis of phase 3 RCTs compared immune checkpoint inhibitors in locally advanced and metastatic cervical cancer. P…
Adding pembrolizumab to standard treatment for advanced cervical cancer is linked to better survival and longer time before the disease prog…